PD-1/PD-L1 Expression and Interaction by Automated Quantitative Immunofluorescent Analysis Show Adverse Prognostic Impact in Patients with Diffuse Large B-cell Lymphoma Having T-cell Infiltration: a Study from the International DLBCL Consortium Program

Ling Li,Ruifang Sun,Yi Miao,Thai Tran,Lisa Adams,Nathan Roscoe,Bing Xu,Ganiraju C. Manyam,Xiaohong Tan,Hongwei Zhang,Min Xiao,Alexandar Tzankov,Carlo Visco,Karen Dybkaer,Govind Bhagat,Wayne Tam,Eric D. Hsi,J. Han van Krieken,Hua You,Jooryung Huh,Maurilio Ponzoni,Andrés J. M. Ferreri,Michael B. Møller,Miguel A. Piris,Mingzhi Zhang,Jane N. Winter,L. Jeffrey Medeiros,George Z. Rassidakis,Christine A. Vaupel,Yong Li,Naveen Dakappagari,Zijun Y. Xu-Monette,Ken H. Young

DOI: https://doi.org/10.1038/s41379-018-0193-5

IF: 8.209

2019-01-01

Modern Pathology

Abstract:Programmed cell death protein 1/programmed cell death protein ligand1 (PD-1/PD-L1) interaction is an important immune checkpoint targeted by anti-PD-1/PD-L1 immunotherapies. However, the observed prognostic significance of PD-1/PD-L1 expression in diffuse large B-cell lymphoma treated with the standard of care has been inconsistent and even contradictory. To clarify the prognostic role of PD-1/PD-L1 expression and interaction in diffuse large B-cell lymphoma, in this study we used 3-marker fluorescent multiplex immunohistochemistry and Automated Quantitative Analysis Technology to assess the CD3+, PD-L1+, and PD-1+CD3+ expression in diagnostic samples and PD-1/PD-L1 interaction as indicated by presence of PD-1+CD3+ cells in the vicinity of PD-L1+ cells, analyzed their prognostic effects in 414 patients with de novo diffuse large B-cell lymphoma, and examined whether PD-1/PD-L1 interaction is required for the prognostic role of PD-1+/PD-L1+ expression. We found that low T-cell tissue cellularity, tissue PD-L1+ expression (irrespective of cell types), PD-1+CD3+ expression, and PD-1/PD-L1 interaction showed hierarchical adverse prognostic effects in the study cohort. PD-1/PD-L1 interaction showed higher sensitivity and specificity than PD-1+ and PD-L1+ expression in predicting inferior prognosis in patients with high CD3+ tissue cellularity ("hot"/inflammatory tumors). However, both PD-1+ and PD-L1+ expression showed adverse prognostic effects independent of PD-1/PD-L1 interaction, and PD-1/PD-L1 interaction showed favorable prognostic effect in PD-L1+ patients without high CD3+ tissue cellularity. Macrophage function and tumor-cell MYC expression may contribute to the PD-1-independent adverse prognostic effect of PD-L1+ expression. In summary, low T-cell tissue cellularity has unfavorable prognostic impact in diffuse large B-cell lymphoma, and tissue PD-L1+ expression and T-cell-derived PD-1+ expression have significant adverse impact only in patients with high T-cell infiltration. PD-1/PD-L1 interaction in tissue is essential but not always responsible for the inhibitory effect of PD-L1+/PD-1+ expression. These results suggest the benefit of PD-1/PD-L1 blockade therapies only in patients with sufficient T-cell infiltration, and the potential of immunofluorescent assays and Automated Quantitative Analysis in the clinical assessment of PD-1/PD-L1 expression and interaction.